Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer--A pooled analysis of PORTEC 1 and 2 trials.

[1]  J. W. Kim,et al.  1A randomized phase III trial of pelvic radiation therapy (PXRT) versus vaginal cuff brachytherapy followed by paclitaxel/carboplatin chemotherapy (VCB/C) in patients with high risk (HR), early stage endometrial cancer (EC): A Gynecologic Oncology Group trial , 2014 .

[2]  A. Usubutun,et al.  Lymphovascular space involvement is the sole independent predictor of lymph node metastasis in clinical early stage endometrial cancer , 2013, Archives of Gynecology and Obstetrics.

[3]  K. Lee,et al.  Lymphovascular space invasion is highly associated with lymph node metastasis and recurrence in endometrial cancer , 2013, The Australian & New Zealand journal of obstetrics & gynaecology.

[4]  H. Putter,et al.  Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data. , 2012, European journal of cancer.

[5]  P. Goodfellow,et al.  Lymphovascular space invasion is an independent risk factor for nodal disease and poor outcomes in endometrioid endometrial cancer. , 2012, Gynecologic oncology.

[6]  Lonneke V van de Poll-Franse,et al.  Long-term outcome and quality of life of patients with endometrial carcinoma treated with or without pelvic radiotherapy in the post operative radiation therapy in endometrial carcinoma 1 (PORTEC-1) trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  H. Putter,et al.  Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial , 2010, The Lancet.

[8]  Hein Putter,et al.  Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  G. Flannelly,et al.  Lymphovascular space involvement in early stage well‐differentiated endometrial cancer is associated with increased mortality , 2009, BJOG : an international journal of obstetrics and gynaecology.

[10]  A. Gadducci,et al.  Lymph-vascular space involvement and outer one-third myometrial invasion are strong predictors of distant haematogeneous failures in patients with stage I-II endometrioid-type endometrial cancer. , 2009, Anticancer research.

[11]  N. Yaegashi,et al.  Endometrioid uterine cancer: histopathological risk factors of local and distant recurrence. , 2009, Gynecologic oncology.

[12]  T. Whelan,et al.  Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis , 2009, The Lancet.

[13]  Andrea Mariani,et al.  Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. , 2008, Gynecologic oncology.

[14]  E. Anteby,et al.  Lymphvascular space involvement compromises the survival of patients with stage I endometrial cancer: results of a multicenter study. , 2007, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[15]  D. Levine,et al.  The incidence of pelvic lymph node metastasis by FIGO staging for patients with adequately surgically staged endometrial adenocarcinoma of endometrioid histology , 2007, International Journal of Gynecologic Cancer.

[16]  G. Thomas,et al.  Endometrial cancer--revisiting the importance of pelvic and para aortic lymph nodes. , 2007, Gynecologic oncology.

[17]  H. Boezen,et al.  Lymphvascular space involvement: an independent prognostic factor in endometrial cancer. , 2005, Gynecologic oncology.

[18]  P. Koper,et al.  Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  M. Maiman,et al.  A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study , 2004 .

[20]  R. Scully,et al.  Unusual Epithelial and Stromal Changes in Myoinvasive Endometrioid Adenocarcinoma: A Study of Their Frequency, Associated Diagnostic Problems, and Prognostic Significance , 2003, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[21]  D. Mutch,et al.  Should the presence of lymphvascular space involvement be used to assign patients to adjuvant therapy following hysterectomy for unstaged endometrial cancer , 2002 .

[22]  P. Koper,et al.  Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial , 2000, The Lancet.

[23]  T. Kawarabayashi,et al.  The grading of lymphovascular space invasion in endometrial carcinoma , 1999, Cancer.

[24]  R. Kurman,et al.  Combined assessment of vascular and myometrial invasion as a model to predict prognosis in stage I endometrioid adenocarcinoma of the uterine corpus , 1992, Cancer.

[25]  B. Bundy,et al.  Surgical pathologic spread patterns of endometrial cancer: A gynecologic oncology group study , 1987, Cancer.

[26]  V. Abeler,et al.  Postoperative External Irradiation and Prognostic Parameters in Stage I Endometrial Carcinoma: CLINICAL AND HISTOPATHOLOGIC STUDY OF 540 PATIENTS , 1980, Obstetrics and gynecology.